IWR-1-endo

For research use only. Not for use in humans.

目录号:S7086

IWR-1-endo Chemical Structure

CAS No. 1127442-82-3

IWR-1-endo是一种Wnt通路抑制剂,在表达 Wnt3A 的 L-细胞中IC50为180 nM,诱导Axin2蛋白水平,并通过稳定Axin骨架破坏复合体来促进β-catenin磷酸化。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 794.43 现货
RMB 900.38 现货
RMB 2050.64 现货
RMB 5151.51 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的IWR-1-endo发表文献61篇:

产品安全说明书

Wnt/beta-catenin抑制剂选择性比较

生物活性

产品描述 IWR-1-endo是一种Wnt通路抑制剂,在表达 Wnt3A 的 L-细胞中IC50为180 nM,诱导Axin2蛋白水平,并通过稳定Axin骨架破坏复合体来促进β-catenin磷酸化。
靶点
Wnt [1]
(L-cells expressing Wnt3A)
180 nM
体外研究

IWR-1 和XAV939作为Wnt通路的可逆抑制剂,在体内外具有相似的药理作用,IWR-1通过与Axin相互作用而发挥效果,而XAV939直接与TNKS结合。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BL21 (DE3) MXHGeY5kfGmxbjDhd5NigQ>? NXqzNlZUQTBibXnudy=> NFq1bHhC[3Srdnn0fUBw\iCQLYTldo1qdnW|IHjlfIFJcXNvdHHn[4VlKGi3bXHuJHRPW0t{IHX4dJJme3OnZDDpckBGe2OqZYLpZ4hq[SClb3zpJGJNOjFiKFTFN{kh[2WubIOgeZNqdmdiYnnveIlvgWyjdHXkJG5CTCtiYYOgd5Vje3S{YYTlJIFnfGW{IEmwJI1qdnNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{NCCHQ{WwJF0hOC5{IN88UU4> NGrTd|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkKzN|MzOCd-MkKyN|M{OjB:L3G+
SW480 MoS4SpVv[3Srb36gZZN{[Xl? NEfMO|QzPCCqcoO= MVPJcohq[mm2aX;uJI9nKHSjbnv5doF{\SCrbjDoeY1idiCVV{S4NEBk\WyuczDhd5Nme3OnZDDhd{Bi[2O3bYXsZZRqd25ib3[gZZhqdjJiYX\0[ZIhOjRiaILzJIJ6KEixZXPod5Qh\HmnLXLhd4VlKG2ndHjv[EwhTUN3MDC9JFIvPSEQvF2u M2jjOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{CxOVE4Lz5{M{ewNVUyPzxxYU6=
HEK293T NX:ze5g1TnWwY4Tpc44h[XO|YYm= Mo\PTY5pcWKrdHnvckBw\iCkZYThMYNie2Wrbj3k[ZBmdmSnboSgZ4Fvd26rY3HsJHdvfDNicHH0bJdigSCrbjDoeY1idiCKRVuyPVNVKGOnbHzzJIJ6KGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBie3OjeTygTWM2OCB;IECuNFI3KM7:TT6= M3XBZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MUmxOVU4Lz5{MkG5NVU2PzxxYU6=
SW480 MlrsSpVv[3Srb36gZZN{[Xl? MoTBOFAhfG9iNEigbJJ{ MV3Jcohq[mm2aX;uJI9nKHSjbnv5doF{\SCrbjDoeY1idiCVV{S4NEBk\WyuczDhd5Nme3OnZDDhd{Bl\We{YXTheIlwdiCxZjDi[ZRiKGOjdHXubY4h[W[2ZYKgOFAhfG9iNEigbJJ{NCCLQ{WwJF0hOC5{NTFOwG0v NEOzRpA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{ewNVUyPyd-MkO3NFE2OTd:L3G+
L-Wnt-STF NXTBdZRxTnWwY4Tpc44h[XO|YYm= MnXhNlQhcHK| NELESVZKdmirYnn0bY9vKG:oIGTOT3MuOiCrbjDtc5V{\SCOLWfueE1UXEZiY3XscJMh[XO|ZYPz[YQh[XNiZHnzdpVxfGmxbjDv[kBYdnRic3nncoFtcW6pIHHmeIVzKDJ2IHjyd{BjgSCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO|YYmsJGlEPTBiPTCwMlA2PiEQvF2u MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV{N{e5Nkc,OjR3Mke3PVI9N2F-
L-Wnt-STF MoHqSpVv[3Srb36gZZN{[Xl? NXfTNopzOjRiaILz M3HPb2lvcGmkaYTpc44hd2ZiVF7LV{0yKGmwIH3veZNmKExvV370MXNVTiClZXzsd{Bie3Onc4Pl[EBieyCmaYPyeZB1cW:wIH;mJHdvfCC|aXfuZYxqdmdiYX\0[ZIhOjRiaILzJIJ6KGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBie3OjeTygTWM2OCB;IECuNVMyKM7:TT6= NEn2UIU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEWyO|c6Oid-MkS1Nlc4QTJ:L3G+
HT29 MnnZSpVv[3Srb36gZZN{[Xl? NVLXdJN{OjRiaILz MlPNTY5pcWKrdHnvckBw\iCZboSgd4lodmGuaX7nJIlvKGi3bXHuJGhVOjliY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBj\XSjLXPheIVvcW5vbXXkbYF1\WRiVHPmM2xm\iC2cnHud4NzcXC2aX;uZYwh[WO2aY\peJkh[W[2ZYKgNlQhcHK|IHL5JIR2[WxibIXjbYZmemG|ZTDy[ZBwenSncjDn[Y5mKGG|c3H5JJJmdGG2aY\lJJRwKGOxboTyc4wtKEmFNUCgQUAzPC52IN88UU4> M1q0UlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUWwOFg6Lz5{NEm1NFQ5QTxxYU6=
DLD1 NYD1VWVLTnWwY4Tpc44h[XO|YYm= M4rMeFExKHWP MWLJcoR2[3Srb36gc4YhSXirbkKgbY4hcHWvYX6gSGxFOSClZXzsd{BwfmW{ZYjwdoV{e2mwZzDJW3IuUVNiYYPz[ZN{\WRiYYOg[IVkemWjc3WgbY4hX262IIDheIh4[XliYXP0bZZqfHliYYSgNVAhfU1iYomgV3RHKHKncH;yeIVzKGG|c3H5JI1mfGixZB?= NITuZmg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUGyOVE2Pid-MUmxNlUyPTZ:L3G+
HEK293 MlewSpVv[3Srb36gZZN{[Xl? MmfwSIl{eGyjY3Xt[Y51KG:oIFnXVk1RSiCocn;tJGF5cW5{IHnuJGhGUzJ7MzDj[YxteyCkeTDX[ZN1\XKwIHLsc5QhdWW2aH;k M1XpZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MUK1NVU3Lz5zOUGyOVE2PjxxYU6=
DLD1 NH7UNoFHfW6ldHnvckBie3OjeR?= MW\Jcohq[mm2aX;uJI9nKEG6aX6yJJBzd3SnaX6g[IVoemGmYYTpc44hcW5iaIXtZY4hTEyGMTDj[YxteyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM> M1jlVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MUK1NVU3Lz5zOUGyOVE2PjxxYU6=
DLD1 MnvySpVv[3Srb36gZZN{[Xl? MVLJcoR2[3Srb36gc4YhSXirbkKgZYNkfW23bHH0bY9vKGmwIHj1cYFvKESOREGgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4hXGi{NEGgdIhwe3Cqb4L5cIF1\WRiYnX0ZU1k[XOnaX6gcIV3\Wy|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>? NIXtcFU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUGyOVE2Pid-MUmxNlUyPTZ:L3G+
DLD1 MULGeY5kfGmxbjDhd5NigQ>? MnflTY5lfWO2aX;uJI9nKEG6aX6yJIFk[3WvdXzheIlwdiCrbjDoeY1idiCGTFSxJINmdGy|IHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKFOnckO3JJBpd3OyaH;yfYxifGWmIHLleIEu[2G|ZXnuJIxmfmWuczDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN? NVfJTGlNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmxNlUyPTZpPkG5NVI2OTV4PD;hQi=>
DLD1 NUHlSXNpTnWwY4Tpc44h[XO|YYm= NWTRTIZ5TGWlcnXhd4UhcW5iYnX0ZU1k[XOnaX6gZYNkfW23bHH0bY9vKGmwIHj1cYFvKESOREGgZ4VtdHNiZYjwdoV{e2mwZzDpckBCWENibYX0ZY51 NHv3UJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUGyOVE2Pid-MUmxNlUyPTZ:L3G+
DLD1 M1rRXWZ2dmO2aX;uJIF{e2G7 MX2yJIhzew>? NFfYOYNKdmS3Y4Tpc44hd2ZiQYjpclIhe3SjYnnsbZpifGmxbjDpckBpfW2jbjDEUGQyKGOnbHzzJIF{e2W|c3XkJIF{KGSnY4LlZZNm\CC2cnHud4NzcXC2aX;uJI9nKEG6aX6yJIFnfGW{IEKgbJJ{KGK7IGLUMXBEWiCvZYToc4Q> M3fReVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MUK1NVU3Lz5zOUGyOVE2PjxxYU6=
DLD1 NIHIdlhHfW6ldHnvckBie3OjeR?= MlLQTY5lfWO2aX;uJI9nKEG6aX6yJIFk[3WvdXzheIlwdiCrbjDoeY1idiCGTFSxJINmdGy|IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKG[{ZXWgZoV1[S2lYYPlbY4hdGW4ZXzzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?= MmnTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlzMkWxOVYoRjF7MUK1NVU3RC:jPh?=
DLD1 MYrGeY5kfGmxbjDhd5NigQ>? MV\JcoR2[3Srb36gc4YhSXirbkKgd5Ri[mmuaYrheIlwdiCrbjDoeY1idiCGTFSxJINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiV370M4JmfGFvY3Hz[YlvKHCjdHj3ZZk> M1HhcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MUK1NVU3Lz5zOUGyOVE2PjxxYU6=
DLD1 Ml6zSpVv[3Srb36gZZN{[Xl? M{jpWWlv\HWldHnvckBw\iCDeHnuNkBi[2O3bYXsZZRqd25iaX6gbJVu[W5iRFzENUBk\WyuczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCVZYKzN{BxcG:|cHjvdplt[XSnZDDi[ZRiNWOjc3XpckBt\X[nbIOgZpkhX2W|dHXyckBjdG:2IHHuZYx6e2m| NGf6e|M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUGyOVE2Pid-MUmxNlUyPTZ:L3G+
DLD1 M3T0SmZ2dmO2aX;uJIF{e2G7 NGLNd45KdmS3Y4Tpc44hd2ZiQYjpclIh[WOldX31cIF1cW:wIHnuJIh2dWGwIFTMSFEh[2WubIOgZpkhX2W|dHXyckBjdG:2IHHuZYx6e2m| MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTF{NUG1Okc,OTlzMkWxOVY9N2F-
DLD1 NWXTXYZsTnWwY4Tpc44h[XO|YYm= NWS5cFVnOSC2bzCyNEB2VQ>? MWOyOEBpenN? MlLjTY5pcWKrdHnvckBw\iC2YX7rfZJie2ViaX6gbJVu[W5iRFzENUBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIGTDSk1l\XCnbnTlcpQhfHKjboPjdolxfGmxbnHsJIFkfGm4aYT5JIF1KDFidH:gNlAhfU1iYX\0[ZIhOjRiaILzJIJ6KGS3YXygcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6 MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV{N{e5Nkc,OjR3Mke3PVI9N2F-
DLD1 NVvBUWhMS3m2b4TvfIlkcXS7IHHzd4F6 NHi2S4gyKHSxIEKwJJVO NHmxZ5kyOCCmYYnz Ml;KR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gSGxFOSClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjdDCxJJRwKDJyIIXNJI1m[XO3cnXkJI9vKGSjeTCxNEBjgSClconzeIFtKH[rb3zleEB{fGGrbnnu[y=> MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV{N{e5Nkc,OjR3Mke3PVI9N2F-
HT29 M3[1dGZ2dmO2aX;uJIF{e2G7 M33SVFI2KHWP MYiyOEBpenN? NULsNXZsUW6qaXLpeIlwdiCxZjDXcpQhe2mpbnHsbY5oKGmwIHj1cYFvKEiWMkmgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCkZYThMYNifGWwaX6tcYVlcWG2ZXSgWINnN0ynZjD0doFve2O{aYD0bY9v[WxiYXP0bZZqfHliYYSgNlUhfU1iYX\0[ZIhOjRiaILzJIJ6KGS3YXygcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6KHKnbHH0bZZmKHSxIHPvcpRzd2x? MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl3MES4PUc,OjR7NUC0PFk9N2F-
HT29 M1TqcWZ2dmO2aX;uJIF{e2G7 MVqyOUB2VQ>? MmOyNlQhcHK| MWXJcohq[mm2aX;uJI9nKFewdDDzbYdv[WyrbnegbY4hcHWvYX6gTHQzQSClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJIJmfGFvY3H0[Y5qdi2vZXTpZZRm\CCWY3[vUIVnKHS{YX7zZ5JqeHSrb37hcEBi[3Srdnn0fUBifCB{NTD1UUBi\nSncjCyOEBpenNiYomg[JVidCCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO|YYmgdoVt[XSrdnWgeI8h[2:wdILvcEBqdiCycnXz[Y5k\SCxZjDHV2suO2KndHGgbY5pcWKrdH;yJGxqS2x? NGHvfYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm1NFQ5QSd-MkS5OVA1QDl:L3G+
HT29 MYnGeY5kfGmxbjDhd5NigQ>? MUOyOUB2VQ>? NITyZ3gzPCCqcoO= M{jR[2lvcGmkaYTpc44hd2ZiV370M4JmfGFvY3H0[Y5qdiC|aXfuZYxqdmdiaX6gbJVu[W5iSGSyPUBk\WyuczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCjeHnuNkBuWk6DIHX4dJJme3Orb36gZZQhOjVidV2gZYZ1\XJiMkSgbJJ{KGK7IIH1ZY51cXSjdHn2[UBz\WGuLYTpcYUhWEOUIHHzd4F6 Mm[0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NUC0PFkoRjJ2OUWwOFg6RC:jPh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
E-cadherin / N-cadherin / Snail / Vimentin; 

PubMed: 26450645     


Western blot analyses showing protein expression patterns of the EMT markers according to IWR-1 dose and exposure time. β-Actin was used as a loading control.

p-Akt / Akt; 

PubMed: 26450645     


Western blot analysis showing that IWR-1 decreased the phosphorylation of Akt in a concentration- and time-dependent manner, respectively.

Survivin; 

PubMed: 26450645     


Western blot analysis showing that IWR-1 decreased the survivin expression in a concentration- and time-dependent manner, respectively.

26450645

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

溶解度 (25°C)

体外 DMSO 21 mg/mL (51.28 mM)
Water Insoluble
Ethanol Insoluble

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 409.44
化学式

C25H19N3O3

CAS号 1127442-82-3
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

Wnt/beta-catenin Signaling Pathway Map

相关Wnt/beta-catenin产品

Tags: 购买IWR-1-endo | IWR-1-endo供应商 | 采购IWR-1-endo | IWR-1-endo价格 | IWR-1-endo生产 | 订购IWR-1-endo | IWR-1-endo代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID